SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Sharck who started this subject5/17/2001 11:34:59 AM
From: besttrader   of 37746
 
Genome Thera (GENE) 7.65 +0.19: Friedman Billings initiates coverage with an ACCUMULATE and a price target of $10; believes that GENE stands a strong chance of receiving a high percentage of anticipated revenues given its balance of near-term, mid-term and long-term sources of revenue; the revenue sources are comprised of license fees from genomics alliances, subscription fees to its microbial genomics database, PathoGenome, and contract revenue from its well-reputed GTC Sequencing Center.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News